Howard Hughes Medical Institute’s Regeneron Pharmaceuticals REGN Stock Holding History

Howard Hughes Medical Institute’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-22	Closed	-$17K	–	388
2025 Q4	$17K	Hold	22	–	–	0.01%	129
2025 Q3	$12.4K	Hold	22	–	–	0.01%	177
2025 Q2	$11.6K	Buy	+22	New	+$12.3K	﹤0.01%	176
2015 Q1	–	Sell	-1,092	Closed	-$448K	–	188
2014 Q4	$448K	Sell	1,092 -1,157	-51%	-$455K	0.12%	92
2014 Q3	$811K	Buy	2,249 +1,862	+481%	+$624K	0.18%	62
2014 Q2	$109K	Buy	+387	New	+$115K	0.02%	118

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Howard Hughes Medical Institute's REGN Position: Q1 2026 in Review

Howard Hughes Medical Institute sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 22 shares — an estimated $17K sold.

Howard Hughes Medical Institute first reported a position in REGN in Q2 2014 and held it in 6 quarters. The position peaked at $811K in Q3 2014. 1,399 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Howard Hughes Medical Institute reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Howard Hughes Medical Institute sold 22 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $17K.
Howard Hughes Medical Institute first reported a position in Regeneron Pharmaceuticals in Q2 2014 and held it in 6 quarters.
Howard Hughes Medical Institute's Regeneron Pharmaceuticals position peaked at $811K in Q3 2014.
1,399 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Howard Hughes Medical Institute's 13F filing for Q1 2026, filed 15 May 2026.